Manufacturers trying to carry out these approaches have to offer robust validation data to demonstrate their equivalence to pharmacopoeial approaches. As these new technologies emerge, the WHO emphasizes the significance of a radical risk evaluation and validation process. Operational controls, including in-depth SOPs and operator instruc